Literature DB >> 2819670

Oesophageal cancer in South Africa. A review of 1926 cases.

A Mannell1, W Murray.   

Abstract

From November 1985 to August 1988, the National Study Group for Oesophageal Cancer collected and centralized data on 1926 new cases of oesophageal cancer in South Africa. A standard data sheet was used to record the age, sex, and condition of the patients, the site, length, and circumferential extent of the tumor, the presence of extraoesophageal and distant spread, associated pulmonary disease, and the therapeutic technique selected for each case. A computerized audit of cases was reviewed to examine the performance status, stage of disease, and methods of treatment. There were 1438 men and 488 women (male to female ratio, 3 to 1) and their ages ranged from 20 to 100 years (mean age, 56 years). Twenty-four percent were admitted to the hospital with total dysphagia. The performance status was excellent or good in 49% of the patients and fair in 29%. Those in poor or desperate condition included 13% of the patients with oesophago-airway fistulae. The most common site of cancer was the mid-thoracic oesophagus (53% of the cases), but 8.3% had tumors longer than 10 cm involving two or more oesophageal segments. Using the American Joint Committee (AJC) system of staging, 2.8% of the patients were assessed as Stage I, 19.8% as Stage II, and 77.4% as Stage III. Thirty-seven percent of the patients were treated by oesophageal intubation, 35% by radiation therapy, and 22% by chemotherapy. Surgery was selected for 17% of the patients. Although the number of young patients appears to have increased, the typical South African patient with oesophageal cancer is a man 56 years of age, in excellent or good condition, with a mid-thoracic tumor 6 cm in length and Stage III disease. This patient is frequently treated by palliative intubation of the oesophagus but may be a candidate for more intensive anti-cancer therapy.

Entities:  

Mesh:

Year:  1989        PMID: 2819670     DOI: 10.1002/1097-0142(19891215)64:12<2604::aid-cncr2820641233>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer.

Authors:  M Sur; L Taylor; K Cooper; R K Sur
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

2.  13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial.

Authors:  C F Slabber; G Falkson; W Burger; L Schoeman
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Palliation of carcinoma of the oesophagus with brachytherapy and the Didcott dilator.

Authors:  R K Sur; C C Didcott; C V Levin; M Kulhavy; B Donde; M Schafer; J Gavenescu
Journal:  Ann R Coll Surg Engl       Date:  1996-03       Impact factor: 1.891

4.  Frequent occurrence of esophageal cancer in young people in western Kenya.

Authors:  R K Parker; S M Dawsey; C C Abnet; R E White
Journal:  Dis Esophagus       Date:  2009-05-15       Impact factor: 3.429

5.  Systematic review and meta-analysis of esophageal cancer in Africa: Epidemiology, risk factors, management and outcomes.

Authors:  Akwi W Asombang; Nathaniel Chishinga; Alick Nkhoma; Jackson Chipaila; Bright Nsokolo; Martha Manda-Mapalo; Joao Filipe G Montiero; Lewis Banda; Kulwinder S Dua
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

6.  Five-year single-centre experience of carcinoma of the oesophagus from Blantyre, Malawi.

Authors:  Melita A Gordon; Leo Masamba; John David Chetwood; Peter J Finch; Anstead Kankwatira; Jane Mallewa
Journal:  BMJ Open Gastroenterol       Date:  2018-10-15

7.  Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study.

Authors:  Geoffrey C Buckle; Alita Mrema; Michael Mwachiro; Yona Ringo; Msiba Selekwa; Gift Mulima; Fatma F Some; Blandina T Mmbaga; Gita N Mody; Li Zhang; Alan Paciorek; Larry Akoko; Paul Ayuo; Stephen Burgert; Elizabeth Bukusi; Anthony Charles; Winnie Chepkemoi; Gladys Chesumbai; Bongani Kaimila; Aida Kenseko; Kitembo Salum Kibwana; David Koech; Caren Macharia; Ezekiel N Moirana; Beatrice Paul Mushi; Alex Mremi; Julius Mwaiselage; Ally Mwanga; Jerry Ndumbalo; Gissela Nvakunga; Mamsau Ngoma; Margaret Oduor; Mark Oloo; Jesse Opakas; Robert Parker; Saruni Seno; Ande Salima; Furaha Servent; Andrew Wandera; Kate D Westmoreland; Russell E White; Brittney Williams; Elia J Mmbaga; Katherine Van Loon
Journal:  BMC Cancer       Date:  2022-01-19       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.